Bcl9L Antibody | 6213

Bcl9L Antibody | 6213 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: Predicted species reactivity based on immunogen sequence: Mouse: (100%) , Rat: (100%)

Immunogen: Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L.
The immunogen is located within amino acids 20 - 70 of Bcl9L.

Research Area: Cancer, Cell Cycle

Tested Application: E, WB, IHC-P, ICC, IF

Application: Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL and immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.

Positive Control 1: Cat. No. 1201 - HeLa Cell Lysate

Positive Control 2: Cat. No. 17-001 - HeLa Cell Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 165 kDa
Observed: 195 kDa

Validation: N/A

Isoform: N/A

Purification: Bcl9L Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: Bcl9L antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Bcl9L Antibody: BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF) -mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.